Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

BACKGROUND: Anti-PD1/PDL1 immune checkpoint inhibitors (ICI) transformed the prognosis of patients with advanced non-small cell lung cancer (NSCLC). However, the response rate remains disappointing and toxicity may be life-threatening, making urgent identification of biomarkers predictive for effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mogenet, Alice, Finetti, Pascal, Denicolai, Emilie, Greillier, Laurent, Boudou-Rouquette, Pascaline, Goldwasser, François, Lumet, Gwenael, Ceccarelli, Michele, Birnbaum, Daniel, Bedognetti, Davide, Mamessier, Emilie, Barlesi, Fabrice, Bertucci, François, Tomasini, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507965/
https://www.ncbi.nlm.nih.gov/pubmed/37726776
http://dx.doi.org/10.1186/s12967-023-04463-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507965/
https://www.ncbi.nlm.nih.gov/pubmed/37726776
http://dx.doi.org/10.1186/s12967-023-04463-2

Ejemplares similares